The 11th International AIDS Society Conference on HIV Science

Download All
July 18-21, 2021; Virtual
CCO is the official provider of online scientific analysis for IAS 2021 through rapid post-conference webinars by expert faculty, Capsule Summaries, downloadable slides, podcasts, and ClinicalThought commentaries.


Capsule Summary Slidesets

Patients with HIV-1 RNA <40 copies/mL and target not detected outcome similar with dual DTG/3TC vs triple or quadruple TAF-based regimens.

Released: July 22, 2021

At Week 124, 80% of patients still demonstrated virologic suppression on monthly injectable cabotegravir + rilpivirine, with no new safety signals since the Week 96 analysis.

Released: July 21, 2021

After 24 weeks of 3-drug induction therapy in treatment-naive patients, islatravir plus doravirine dual therapy was generally well tolerated through 96 weeks.

Released: July 20, 2021

Large, retrospective analysis illustrates viral suppression with and tolerability of dolutegravir-based regimens in children and adolescents who were treatment naive or suppressed on previous regimens.

Released: July 22, 2021

In this real-world study, healthcare staff across a variety of clinic types found the implementation of monthly injectable cabotegravir + rilpivirine both feasible and acceptable despite disruptions due to COVID-19.

Released: July 22, 2021

Reduced doses and/or shorter durations of linezolid are associated with similar efficacy but improved safety.

Released: July 26, 2021

After 2-week oral lead-in, treatment with oral or subcutaneous lenacapavir plus FTC/TAF associated with high rates of virologic suppression.

Released: July 24, 2021

Adherence to the dapivirine vaginal ring and oral PrEP was higher than anticipated over 12 months, with rates reaching 50% to 59% depending on the modality.

Released: July 24, 2021

While the number of PrEP breakthrough infections was small, there was a high frequency of ART resistance in HIV-infected persons on TDF-based PrEP in Kenya, Zimbabwe, Eswatini, and South Africa.

Released: July 24, 2021

In patients with multidrug-resistant HIV-1 infection, lenacapavir in combination with an optimized background regimen demonstrated a high rate of virologic suppression, a clinically meaningful increase in CD4+ cell count, and no discontinuation of study therapy due to adverse events through 26 weeks.

Released: July 22, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Janssen Therapeutics, Division of Janssen Products, LP
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.